Giant Biogene (02367.HK) Popular Stock Analysis Report

As an enterprise in the household and personal care products industry under the consumer defensive sector, Giant Biogene (02367.HK) has recently attracted market attention mainly due to its global cooperation agreement with Sweden’s biotech company Nordberg Medical [1][2][3]. Signed on December 21, 2025, this agreement grants the other party the right to develop the company’s patented recombinant collagen technology in global markets except for mainland China, for tissue regeneration products in the medical aesthetics field. As a company with regulatory approvals in 33 markets and a direct sales network covering more than 20 countries, Nordberg Medical will provide Giant Biogene with mature channels to help it quickly enter the global injectable medical aesthetics market, which is expected to reach $10 billion in 2026 [1]. In addition, the company obtained China’s first Class III medical device registration certificate for recombinant type I natural sequence collagen facial injectables at the end of October 2025, marking an important leap from the To C consumer end to the To B professional end [3].

In terms of price and trading volume, the company’s recent stock price performance has been weak; the current price of $33.28 is down about 61% from the May 2025 high of $87.10, approaching the 52-week low of $33.00 [0]. In terms of valuation, its P/E ratio is 13.84x and P/B ratio is 3.41x, significantly lower than the industry average [0]; the estimated 2026 PE is only half of the average valuation of peer companies [4]. In terms of liquidity, the current ratio of 4.87 and quick ratio of 4.65 indicate the company has strong short-term solvency [0].

Although Giant Biogene’s recent stock price performance has been poor, its large-scale share repurchase plan covering 10% of issued shares and high dividend yield of 4.7% demonstrate management’s confidence in the company’s intrinsic value [4]. At the same time, institutional investors such as Goldman Sachs (target price: HK$71) and Bernstein (target price: HK$70) hold a positive attitude towards its long-term development [4]. This phenomenon indicates that the market still has confidence in the company’s technical strength and growth potential brought by global cooperation; the short-term stock price decline may be more affected by market sentiment and capital flows.

: The cooperation with Nordberg Medical has created an innovative model for Chinese medical aesthetics technology to go global [1]; with the help of the other party’s mature channels, the company can quickly expand into global markets and seize share in the injectable medical aesthetics market.

: Short-term price volatility is high, with a decline of more than 40% in the past three months; investors need to be alert to fluctuations caused by short-term capital flows [0]; global expansion faces uncertainties such as regulatory approvals and market competition; the company’s performance growth slowed in the first half of 2025 and gross margin declined slightly, posing a risk of growth slowdown [3]; the recombinant collagen track is highly competitive, requiring continuous innovation to maintain a leading position.

Giant Biogene (02367.HK) has become a popular stock due to its global cooperation agreement with Nordberg Medical, which will help it quickly enter the global injectable medical aesthetics market. Although the recent stock price has fallen significantly and valuation is at a low level in the industry, management and institutional investors hold a positive attitude towards its long-term development; however, risks such as short-term volatility, uncertainties in global expansion, and industry competition still need to be noted.